Hematúria anemitzant. Quadre quotidià amb desenllaç inesperat.
1
Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 50:7- 33, 2000.
2
Figlin RA: Renal cell carcinoma: Manage- ment of advanced disease. J Urol 161:381-386, 1999.
3
Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology 2005 Aug;236(2):441-50.
4
Sobin LH, Gospodariwicz M, Wittekind C (eds). TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, 2009: pp. 255-257.
5 Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002. 6 Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW. Prognostic nomgram for sunitinib in patients with metastatic renal cell carcin- oma. Cancer 2008;113:1552–8. 7 Borje Ljungberg , Nigel C. Cowan, Damian C. Hanbury, Milan Hora, Markus A. Kuczyk, Axel S. Merseburger, Jean-Jacques Patard, Peter F.A. Mulders, Ioanel C. Sinescu. EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. Eur Urol July: 58 (2010) 398–406. 8
Lam JS, Breda A, Belldegrun AS, Figlin RA. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol 2006;24:5565–75.
9 Amato, R. J. (2000). Chemotherapy for renal cell carcinoma. Seminars in Oncology, 27, 177–186. 10 Nyhan MJ, O’Sullivan GC, McKenna SL, et al. Role of the VHL (von Hippel–Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans 2008;36(pt 3): 472–8. 11 Atkins, M. B., Ernstoff, M. S., Figlin, R. A., Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF. (2007). Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clinical Cancer Research, 13, 667s–670s. 12 Heng, D. Y., Xie, W., Regan, M. M., Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al. (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Journal of Clinical Oncology, 27, 5794–5799. 13 Klatte, T., Rao, P. N., de Martino, M., et al. (2009). Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. Journal of Clinical Oncology, 27, 746–753. 14 Motzer, R. J., Michaelson, M. D., Redman, B. G., et al. (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 24, 16–24. 15 Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrect- omy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6. 16 Ljungberg, B., Landberg, G., & Alamdari, F. I. (2000). Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scandinavian Journal of Urology and Nephrology, 34, 246–251. 17 Shuch B, Riggs SB, LaRochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008; 102:692–696. 18 Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009; 182:881 – 886.
Annals d’Urologia 2013 | ARTICLES | 9